Navigation Links
Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
Date:3/13/2009

NEW YORK, March 13 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually. Applications will be accepted twice a year, with up to $2.5 million in funding available each spring and another $2.5 million available in the fall.

First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinson's research as part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies -- thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson's disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.

Under the 2009 TDI program, MJFF primarily seeks to support pre-clinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical pre-clinical studies necessary for developing, optimizing and evaluating therapeutic strategies that, if successful, can move into human testing.

The first three years of TDI were enthusiastically received by industry researchers. To date the Foundation has awarded nearly $12.8 million total under the initiative for 24 industry-led projects.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded nearly $140 million in research directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gene Network Sciences Announces Michael Gilman as Board Member
2. Nyenrode Honorary Doctorate for Professor Michael E. Porter
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
5. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decades Real Nutritional Heroes
8. Xceleron Names Michael Butler as President & CEO
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... September 18, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... presentation at the ServiceMax Maximize 2017 conference. , What: Digital Transformation in Medical ...
(Date:9/15/2017)... ... September 15, 2017 , ... San Diego based ... ‘Internal Seed B’ round of financing, totaling $600,000. The round was entirely ... ‘SAFE’ documentation structure at a company valuation of $10M. , Grolltex, ...
(Date:9/14/2017)... (PRWEB) , ... September 14, 2017 , ... ... innovative minds in pharma and biotech at the third annual DrugDev Summit, November ... that brings together the world’s most progressive clinical research leaders for best practice ...
(Date:9/14/2017)... ... 14, 2017 , ... Boston Strategic Partners, Inc. (BSP), a ... and Outcomes Research (HEOR) and ‘big data’ to provide in-depth analysis of pneumonia ... exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
Breaking Biology News(10 mins):